#PancreaticCancer #CancerResearch #ClinicalTrials
markets.businessinsider.com
HUTCHMED Initiates Phase III Stage of the Ongoing Trial of the Combination of Surufatinib and Camrelizumab for Treatment-Naïve Pancreatic Ductal Adenocarcinoma
HONG KONG and SHANGHAI and FLORHAM PARK, N. J. , Jan. 05, 2026 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited ("HUTCHMED") (Nasdaq/AIM:HCM; HKEX:13) today announces that it has initiated the Phase III part of the Phase II/III trial to evaluate the efficacy of the combination of surufatinib, camrelizumab, nab-paclitaxel and gemcitabine as a first-line treatment for patients with metastatic pancreatic ductal adenocarcinoma ("PDAC") in China.
C
#CancerResearch #PancreaticCancer #ClinicalTrials
www.courant.com
Pancreatic cancer is among the deadliest cancers. A new drug being tested at Penn is giving patients and doctors hope
PHILADELPHIA -- Irene Blair was expected to have another six to eight months to live in June, after her pancreatic cancer rapidly advanced to stage 4 less than a year after her initial diagnosis.
